FUS R521C

The FUS R521C variant is classified as pathogenic by ClinVar based on multiple expert submissions, and its extreme rarity in the general population (frequency of 6.84e-07, or approximately 1 in 1.46 million chromosomes) strongly supports its disease-causing role in familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). This variant affects the fused in sarcoma (FUS) protein, an RNA-binding protein that normally shuttles between the nucleus and cytoplasm to regulate gene expression, RNA splicing, and DNA damage responses. The AlphaFold2 structure prediction of FUS R521C yields an average confidence score (pLDDT) of 50.3, which falls well below the threshold of 70 typically required for reliable structural interpretation. This low confidence likely reflects intrinsic disorder in FUS, as RNA-binding proteins often contain flexible, unstructured regions that resist stable folding. Given this substantial uncertainty throughout the predicted structure, detailed structural analysis of specific conformational changes caused by the R521C mutation cannot be reliably performed. The prediction serves primarily to highlight the disordered nature of this protein rather than to reveal specific atomic-level changes. Despite limitations in structural prediction, extensive experimental evidence reveals how R521C drives ALS pathology through multiple mechanisms. Studies show that mutant FUS R521C forms abnormally stable complexes with normal FUS protein, extending its half-life from 11.6 to 21 hours and disrupting interactions with the DNA repair machinery, particularly HDAC1 [1]. This leads to accumulation of DNA damage markers in over 50% of cortical and spinal motor neurons [1]. The mutation also causes widespread RNA splicing defects, including abnormal processing of the brain-derived neurotrophic factor (BDNF) gene, which is critical for neuronal survival [1]. More recent work demonstrates that FUS mutations increase synaptic protein levels and glutamate release, making motor neurons hyperactive and vulnerable to excitotoxic death—a process where excessive nerve signaling leads to toxic calcium overload [2][3]. The convergence of DNA damage, RNA processing defects, and synaptic dysfunction explains the progressive motor neuron death characteristic of ALS in R521C carriers. Interestingly, mouse models of R521C show predominantly nuclear localization rather than the cytoplasmic protein clumps seen in patient tissues, yet still develop dendritic simplification (reduced branching of neuronal projections) and loss of synaptic connections [2][3]. These findings suggest that nuclear dysfunction may be sufficient to trigger disease, challenging earlier assumptions that cytoplasmic aggregation is the primary driver. The pathogenic classification, extreme rarity, and multiple converging mechanisms of neuronal injury establish R521C as a definitive ALS-causing mutation, though the low-confidence structural prediction prevents atomic-level analysis of how the arginine-to-cysteine substitution alters protein folding or interactions.